Practitioner's Corner with Dr Seth Bilazarian

Hypertension Guidelines: Clear as Mud Dr. Bilazarian gives his take on JNC 8 and the implications for the practicing physician when professional societies disagree on guidelines.
Slide/Lecture Presentation, January 30, 2014
Keeping Positive About Negative Trials The first 4 latebreakers from AHA were 'negative' trials, leaving Dr. Bilazarian disappointed, but upon reflection, he is optimistic about cardiovascular medicine and the merits of medical meetings.
Slide/Lecture Presentation, December 13, 2013
Guidelines Update 'ATP-4' -- Finally! Dr. Bilazarian gives his topline take on the new cholesterol, CV risk, and obesity guidelines.
November 13, 2013
Managing Novel Oral Anticoagulant Transitions To bridge or not to bridge? Dr. Seth Bilazarian examines the data on transitioning patients on and off novel oral anticoagulants and charts the path forward.
October 17, 2013
Cardioversion Turns 50: What's Changed? Cardioversion first saw the light of day in 1963, and to celebrate its birthday, Dr. Seth Bilazarian turns his attention to the procedure, its usage, and the path it's taken over the half century.
Experts And Viewpoints, August 23, 2013
How Is Your 96-Year-Old Patient Doing Post-TAVI? Dr. Seth Bilazarian shares his thoughts on 'aggressive' treatment in the very elderly, why age should no longer be considered a standalone criterion, and the many implications of extreme longevity.
Experts And Viewpoints, August 07, 2013
Cardiologists Are Ageists It's the peg on which we hang our clinical cases and somewhat of a sliding scale. When today's 80 is yesterday's 65, how does age affect the care we give our patients? Dr. Seth Bilazarian explores.
Experts And Viewpoints, July 08, 2013
Renal denervation: Reviewing the latest data Dr Seth Bilazarian did the rounds of the renal-denervation sessions at ACC 2013 and shares his findings—from Symplicity HTN-2 data, pathological reports on the actual location of the nerves in the renal artery, to a review of devices—and his hopes...
March 26, 2013
Adopting novel antiplatelet therapies: What's holding you back? In his presentation at ACC 2013, Dr Bob Harrington argued that it can take practitioners 30 years to adopt new therapeutic regimens. What's holding us back? Ignorance? Habit? Cost? Ineffective interaction with industry in the clinical setting?
March 19, 2013
Finding our way in appropriate-use criteria The initial push-back against AUC seems to have given way to a certain acceptance of "our lot" as shown by a series of presentations (one even humorous!) during ACC 2013.
March 12, 2013
Goodbye CV practice memorabilia, hello ACO perfection! Office renovations give a chance to pause and reminisce about the practice of yesteryear as Dr Seth Bilazarian empties his office drawers of promo knickknacks, dictation audio tapes, prescription pads, and mangy old stethoscopes.
January 16, 2013
Clopidogrel pretreatment: Reading between the (head) lines Research by Gilles Montalescot's group on the association of clopidogrel pretreatment with mortality, CV events, and major bleeding in PCI, is an excellent addition to our knowledge base and—depending on which headline you believe—there's something in it
December 20, 2012
Chest compressions: Radical change to practice? It's supposed to be a foregone conclusion (right?), but one debate at AHA 2012 provided convincing arguments against chest compressions. This could be a major paradigm shift: To compress or not to compress?
November 09, 2012
Forget about fish oil and multivitamins for secondary prevention of CV events There seems to be hope on the horizon for secondary prevention—as shown by promising results with colchicine and PCSK9 here in Los Angeles—but it's time to ditch your fish oil and multivitamins.
November 07, 2012
Frustrated in Los Angeles: Platelet function testing isn't working out From a clinical perspective, it's disappointing that the results of the ARCTIC and TRILOGY angiography substudy do not shine a favorable light on platelet function testing. What's best for our patients?
November 04, 2012
Pradaxa turns 19 (in dog years) As Pradaxa (dabigatran) celebrates its second anniversary since FDA approval, the clock is ticking to 2018, when its first patent is set to expire.
October 23, 2012
What to do about hospital readmission rates As the CMS moves to cut reimbursement based on high rates of hospital readmission for MI, heart failure, and pneumonia, how can cardiologists—working with other healthcare providers, patients, and their families—provide optimum care and keep people out...
October 16, 2012
Physician, are you burning out? Forty-six percent of physician respondents to a recent survey admitted to one of the aspects of burnout, as defined by emotional exhaustion, depersonalization, or a feeling of low personal accomplishment.
October 10, 2012
Keeping up with journals Staying on top of the constant inflow of journals is a daunting task. How do you go about it?
September 27, 2012
Happy 25th birthday, lovastatin (Mevacor)! What next? As we mark an important birthday of the first statin (lovastatin), it's good to celebrate the success of this class of drugs and ponder what the next big thing in prevention of cardiovascular disease will be.
August 31, 2012